Related Experiment Video
Updated: Jul 25, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Comorbidities Associated with Psoriatic Arthritis Compared with Non-psoriatic Spondyloarthritis: A Cross-sectional
Naba Haque1, Rik J Lories1, Kurt de Vlam2
1From the Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, University of Leuven; Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium.N. Haque, MD, MS, PhD Student, Division of Rheumatology, University Hospitals Leuven; R.J. Lories, MD, PhD, Professor, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, University of Leuven, and Division of Rheumatology, University Hospitals Leuven; K. de Vlam, MD, PhD, Consultant, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, University of Leuven, and Division of Rheumatology, University Hospitals Leuven.
Objective:
Psoriatic arthritis (PsA) is a chronic inflammatory skeletal disease associated with health concerns such as obesity, Type II diabetes, dyslipidemia, hypertension (HTN), and cardiovascular (CV) disease. The involvement of these metabolic factors in the pathogenesis, severity, and progression of PsA remains unclear. In our study, we compared comorbidities associated with PsA to those patients with related but non-PsA forms of spondyloarthritis (SpA).
Methods:
The SpA database at the Rheumatology Department of University Hospitals Leuven was analyzed in a cross-sectional manner using the demographic, medical, and laboratory information of 518 patients with PsA and non-PsA SpA. The patients were grouped by their diagnosis and evaluated on the basis of sex, age, education, work status, disease duration, treatment, and type and number of comorbidities. The data were assessed using the chi-square test, Student t test, Fisher's exact test, and logistic regression, including correction for multiple testing.
Results:
Out of the 518 patients (62.74% men, 37.25% women), 53.66% had comorbidities. The PsA group had 262 patients (mean age 58.8 yrs) and the non-PsA SpA group had 256 patients (mean age 44.9 yrs, p < 0.001). The PsA group was found to have more and multiple comorbidities compared with non-PsA SpA (p < 0.001). The CV and metabolic comorbidities were also significantly higher in the PsA group (p < 0.001). Coronary artery disease, HTN, hyperlipidemia, and metabolic syndrome showed a marked difference between the 2 groups (p < 0.05). An increased incidence of malignancy was found in PsA group (p < 0.05).
Conclusion:
Comorbidities and malignancies are increased in patients with PsA compared with non-PsA SpA, irrespective of demographic factors and type of treatment.
More Related Videos
02:28Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation